Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Yahoo! Finance
A groundbreaking insight into the Synovial Sarcoma pipeline has been revealed for the year 2024, compiling data on over 15 companies and more than 20 pipeline drugs. This encompasses all phases of development, from clinical to nonclinical. Therapeutic assessments by various parameters, including product type, stage, route of administration, and molecule type is thoroughly examined. The report further delves into an analysis of inactive products in this medical sector. Global Advancements in Treatment Synovial Sarcoma, a rare malignancy occurring predominantly in the limbs, poses a significant medical challenge due to its propensity for recurrence and metastasis. Advances in targeted therapies and the development of novel drugs are crucial in addressing unmet needs and improving patient outcomes. The latest report provides a panoramic view of emerging treatments and their current standings in the pipeline. Innovation at the Forefront: Emerging Drug Highlights The recent effort
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- Targeted Protein Degradation Industry Forecast to Reach $4.37 Billion by 2034: PROTACs Lead the Charge with Promising Innovations in Oncology [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics, Inc. (NASDAQ: CCCC) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $12.00 price target on the stock, up previously from $8.00.MarketBeat
- C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 DegraderGlobeNewswire
- C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of DirectorsGlobeNewswire
CCCC
Earnings
- 5/8/24 - In-Line
CCCC
Sec Filings
- 12/9/24 - Form 8-K
- 11/21/24 - Form 4
- 11/21/24 - Form 3
- CCCC's page on the SEC website